

# Janet Dancey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11467285/publications.pdf>

Version: 2024-02-01

24  
papers

9,122  
citations

304602

22  
h-index

642610

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

11399  
citing authors

#	ARTICLE	IF	CITATIONS
1	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	0.5	21
2	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. <i>Journal of Clinical Oncology</i> , 2019, 37, 1102-1110.	0.8	53
3	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology</i> , The, 2018, 19, e20-e32.	5.1	87
4	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. <i>Cancer</i> , 2018, 124, 1455-1463.	2.0	41
5	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	5.1	1,612
6	RECIST 1.1 Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016, 62, 132-137.	1.3	1,143
7	RECIST 1.1 Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	1.3	211
8	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	5.1	711
9	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	0.6	140
10	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e396-e406.	5.1	116
11	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology</i> , The, 2013, 14, e407-e416.	5.1	119
12	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 81-114.		0
13	mTOR signaling and drug development in cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 209-219.	12.5	369
14	A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas. <i>Clinical Cancer Research</i> , 2009, 15, 5895-5901.	3.2	101
15	A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 777-783.	1.1	261
16	Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2007, 13, 7401-7406.	3.2	74
17	Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. <i>Cancer</i> , 2007, 110, 1059-1067.	2.0	309
18	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. <i>Investigational New Drugs</i> , 2005, 23, 357-361.	1.2	402

#	ARTICLE	IF	CITATIONS
19	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	0.8	688
20	Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. <i>Investigational New Drugs</i> , 2004, 22, 427-435.	1.2	84
21	Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. <i>Lung Cancer</i> , 2004, 43, 183-194.	0.9	152
22	Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 595-600.	2.0	145
23	Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non-Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 2095-2103.	0.8	2,074
24	Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non-Small-Cell Lung Cancer: A Phase II Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 1194-1194.	0.8	209